Gathering the record
Relay is organizing the evidence and source boundaries.
Mitochondrial-derived peptide
An experimental peptide studied for cell protection and aging-related biology. The body also makes it naturally.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Human evidence located by Relay is observational or biomarker-based rather than a trial of administered Humanin.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
No administered-human dose-ranging or longer-term safety record was located; growth and apoptosis pathways make broad safety assumptions inappropriate.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryPreclinical; no FDA-approved Humanin product. Whether a defined Humanin analog can reach relevant tissues and improve clinical outcomes without disrupting normal cell-death or growth regulation.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Human biomarker associations and laboratory experiments do not establish an administered-human regimen. Humanin analogues also require separate review.
What would fill this gap: A verified administration study for the exact native peptide or specifically named analogue.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published human research measured naturally circulating Humanin rather than administering a standardized Humanin product to test a clinical outcome.
Population: No directly studied human population was verified for this identity.
Design: Observational biomarker research plus laboratory and animal studies
No direct primary administration source was verified for this exact identity.
Mechanisms
Humanin and analogs influence apoptosis, metabolism, and stress-response pathways in laboratory and animal models. Human circulating-level associations do not prove that administration improves outcomes.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Mechanistic, animal, and observational human biomarker evidence; no administered-human efficacy trial located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether a defined Humanin analog can reach relevant tissues and improve clinical outcomes without disrupting normal cell-death or growth regulation.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Administered Humanin clinical evidence: amounts and schedules describe this route record only.
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Association between a natural biomarker and age-related traits does not establish causation or treatment benefit. The section remains incomplete because administered-human exposure, pharmacokinetic, efficacy, and safety evidence are absent. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Observational biomarker study
Human cohorts
Endpoints were not fully described in the current record.
Circulating Humanin was measured in human cohorts and associated with age-related phenotypes.
Study administration: Not stated in the current record.
Limitations: Association does not establish causation or administered-peptide benefit.
Cell and molecular study
Population not stated.
Endpoints were not fully described in the current record.
Cell studies mapped protective signaling and receptor interactions.
Study administration: Not stated in the current record.
Limitations: Laboratory protection does not establish human efficacy or long-term safety.
Controlled animal study
Mice
Endpoints were not fully described in the current record.
A Humanin analog affected metabolic outcomes in mice.
Study administration: Not stated in the current record.
Limitations: Analog, exposure, and species differences limit translation.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 32575074
PMID 15153530
PMID 30004252